$311.97 -2.0 -0.6%
Last Trade - 07/05/21
| Market Cap | £20.47bn |
| Enterprise Value | £17.51bn |
| Revenue | £221.1m |
| Position in Universe | 458th / 6858 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 8.82 | 1.07 | 238.4 | 198.2 | 428.2 | 308.9 | 1,019 | 1,384 | +103.7% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | October 28, 2010 |
| Public Since | February 3, 2016 |
| No. of Shareholders: | 160 |
| No. of Employees: | 5,300 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market (Dual Listing) |
| Shares in Issue | 91,789,823 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | C/O Mourant Governance Services (Cayman),94 Solaris Avenue Camana Bay, BEIJING, 102206, China |
| Web | |
| Phone | +1 345 9494123 |
| Auditors | Ernst & Young Hua Ming |
As of 07/05/21, shares in Beigene are trading at $311.97, giving the company a market capitalisation of £20.47bn. This share price information is delayed by 15 minutes.
Shares in Beigene are currently trading at $311.97 and the price has moved by 0.103k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Beigene price has moved by 41.79% over the past year.
Of the analysts with advisory recommendations for Beigene, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Beigene is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Beigene is scheduled to issue upcoming financial results on the following dates:
Beigene does not currently pay a dividend.
Beigene does not currently pay a dividend.
Beigene does not currently pay a dividend.
To buy shares in Beigene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Beigene are currently trading at $311.97, giving the company a market capitalisation of £20.47bn.
Here are the trading details for Beigene:
Based on an overall assessment of its quality, value and momentum, Beigene is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Beigene are currently priced at $311.97. At that level they are trading at 16.4% discount to the analyst consensus target price of 0.00.
Analysts covering Beigene currently have a consensus Earnings Per Share (EPS) forecast of -13.3024248851 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beigene. Over the past six months, the relative strength of its shares against the market has been -10.16%. At the current price of $311.97, shares in Beigene are trading at 7.88% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Beigene.
Beigene's management team is headed by:
Here are the top five shareholders of Beigene based on the size of their shareholding:
